Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
JANSSEN NZ LIMITED,Fixed-duration ibrutinib plus venetoclax,"Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Leukaemia (SLL), previously untreated, without TP53 mutation",Fixed-duration ibrutinib plus venetoclax (IMBRUVICA),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
